Glenmark has tied up with Spanish firm Cyndea Pharma to develop complex drugs for US and Canada markets.
Following the tie up Glenmark will develop soft-gelatin capsule products under the technology license from the Spanish drug maker. The partnership allows Glenmark to expand its dosage forms and launch new products. Glenmark earns over 35 per cent revenue from US but the market is seeing increased competition and pricing pressure.
Developing an in-house technology for soft-gelatin capsules would have taken longer and the tie up will quicken product launches for Glenmark.
Glenmark's president (North America) Robert Matsuk said as many as 70 per cent of